Orthocell Ltd has released a press release.
Compelling Data Highlights Remplir Competitive Advantage
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Orthocell
- Remplir Approved to Commence Sales in the Hong Kong Market
- 12 Distributors Signed for Remplir Covering 21 States in US
- Remplir Approved to Commence Sales in US$75m Canadian Market
- Replacement Trading Halt
- Pause in Trading
Later from Orthocell
- First Surgical Use of Remplir in US$1.6 Billion US Market
- Record Revenue of $2.73m in June 25 Quarter up 22.8% QoQ
- Orthocell Announces First US Remplir Sales Revenue
- Appendix 4E & Annual Report
- Compelling 81% Success Rate for Remplir
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell